GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (FRA:D8Y0) » Definitions » Inventories, Inventories Adjustments

Sandoz Group AG (FRA:D8Y0) Inventories, Inventories Adjustments : €0 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Inventories, Inventories Adjustments?

Sandoz Group AG's Inventories, Inventories Adjustments for the quarter that ended in Jun. 2024 was €0 Mil.

Sandoz Group AG's quarterly Inventories, Inventories Adjustments declined from Jun. 2023 (€0 Mil) to Dec. 2023 (€-331 Mil) but then increased from Dec. 2023 (€-331 Mil) to Jun. 2024 (€0 Mil).

Sandoz Group AG's annual Inventories, Inventories Adjustments increased from . 20 (€0 Mil) to Dec. 2022 (€-292 Mil) but then declined from Dec. 2022 (€-292 Mil) to Dec. 2023 (€-331 Mil).


Sandoz Group AG Inventories, Inventories Adjustments Historical Data

The historical data trend for Sandoz Group AG's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Inventories, Inventories Adjustments Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Inventories, Inventories Adjustments
-291.70 -331.04

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Inventories, Inventories Adjustments -291.70 - -331.04 -

Sandoz Group AG Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Sandoz Group AG Business Description

Industry
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines